

MircroRNAs in Innate Immunity; the Smart Regulatory Network

Fereshteh Takhiri¹, Hani Keshavarz Alikhani¹, Moustapha Hassan², Massoud Vosough^{1, 2*}

1. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
2. Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

KEYWORDS

MicroRNAs;
Innate Immunity;
Inflammatory processes;
Immune cells

Article Info

Received 2024/12/20;
Accepted 2024/12/28;
Published Online 2024



ABSTRACT

MicroRNAs are regulatory elements at the post-transcriptional level that play a crucial role in all cellular and developmental processes. Numerous studies have demonstrated the substantial role of miRNAs in the development of immune cells, initiation of Toll-like receptors (TLRs) signaling, and production of cytokines in response to damaged-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). MiRNAs contribute to development and regulation of immune system and inflammatory processes by regulating the expression of specific genes. Cancer and autoimmune diseases can arise due to dysregulated expression of some miRNAs involved in innate immune processes. In this review, the key miRNAs influencing immune system response and inflammatory processes and their role in development of immune cells are discussed.

Corresponding Information: Massoud Vosough. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran. Email: masvos@Royaninstitute.org

Copyright © 2024. This is an open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Abbreviations

TLRs: Toll-like receptors; MyD88: Myeloid differentiation primary response 88; IRAK4: IL-1 receptor associated kinase 4; IRAK1/2: IL-1 receptor associated kinase 1/2; TRAF6: TNF receptor-associated factor 6; TAK1: Transforming growth factor- β -activated kinase-1; TAB2: Transforming growth factor- β -activated kinase 1 (TAK1)-binding protein 2; TAB3: Transforming growth factor- β -activated kinase 1 (TAK1)-binding protein 3; NF- κ B : Nuclear factor kappa B; IKK α : inhibitory- κ B kinase α ; IKK β : inhibitory- κ B kinase β

Background

Any dysregulation in the immune system can cause disease or immune system dysfunction. Regulation of the immune system is a precise procedure in which many factors work together accurately. MiRNAs are small, single-stranded, non-coding RNA molecules containing 21–23 nucleotides. These molecules play a substantial role in gene expression and post-transcriptional regulation.

Innate immune system

The immune system is composed of innate and adaptive immune systems (1). The innate immune system serves as the primary defense barrier against pathogens (2). Innate immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages, and neutrophils recognize damaged-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs) (3). These PRRs include nucleotide-binding oligomerization domain-like receptors (NODs), C-type lectin receptors (CLRs), and Toll-like receptors (TLRs) (4). The structure of TLRs, the most well-known receptor in this category, comprises three domains: the extracellular domain, the Toll/interleukin-1 receptor (TIR) domain, and the transmembrane domain (5). Upon pathogen recognition by TLRs, several intracellular signaling pathways are activated. Two cascades are involved in this process: the MyD88-dependent pathway and the Toll/IL-1R domain-containing adaptor-inducing IFN- β (TRIF)-dependent pathway (6). Both pathways trigger nuclear factor kappa B (NF- κ B) signaling, a critical component of the innate immune response (7). Innate immunity in epithelial cells and the regulatory roles of microRNAs and their interaction with TLRs on their surfaces are presented in the figure 1.

Functional activities of miRNA

MiRNAs have emerged as crucial regulatory elements of biological processes. They form intricate networks that regulate cellular differentiation, growth, homeostasis, and development (8–11). Dysregulation of miRNAs is associated with various diseases, particularly cancer (12). The binding of mature miRNAs to a seed region in the 3'UTR of mRNAs leads to the formation of a duplex (the base-pairing of six to eight nucleotides) at the 5' end of the miRNA (13).

This duplex facilitates the assembly of the RNA-induced silencing complex (RISC) with Argonaut 2 (Ago2), which triggers mRNA degradation, destabilization, or translation inhibition (14). A single miRNA can modulate the expression of multiple proteins by targeting several mRNAs. It is worth noting that a single mRNA sequence may contain seed regions for multiple miRNAs, potentially enabling the synergistic action of several miRNAs on protein production (15).

MiRNAs and immune system regulation

Numerous studies have highlighted that, miRNAs play a significant role in regulating immunological responses, including the development, maturation, activation, functioning, and differentiation of hematopoietic progenitor cells into either the lymphoid or myeloid lineages (16). MiRNAs have been shown to influence both innate and adaptive immune system regulation. The innate immune response, which serves as the trigger for inflammatory responses is also subjected to regulation by microRNAs (17, 18).

MiRNAs and innate immunity cells

MiRNAs play crucial roles in certain mechanisms associated with the development and function of myeloid cells. The processes governing the development and function of myeloid cells are among the most well characterized biological functions in terms of miRNA regulation. Here we highlighted some miRNAs that are involved in regulating these processes.

MiR 155 and miR 146a are key regulators in controlling the development of macrophages and immunity. miR 155 is significantly induced in macrophages and dendritic cells by NF κ B and activator protein 1 (AP 1) in response to a broad range of TLRs and cytokine signal (19, 20).

MiR-233 has been introduced as the first miRNA that changes the fate of granulocytes and contributes to their differentiation (21). Additionally, the growth of NK cells is modulated by miR-181 through inducing notch signaling (22).




Figure 1. Innate immunity in epithelial cells and the regulatory roles of microRNAs. TLRs on epithelial cells are activated by microbial stimuli (e.g., bacteria, viruses, and fungi). TLR activation establishes downstream signaling via the MyD88 adaptor molecule. On the other hand, involved IRAK4, IRAK1/2, and TRAF6, leading to the activation of TAK1, TAB2, and TAB3 complexes. NF- κ B signaling cascade is activated through IKK α , IKK β , p50 and p56 and this induces expression of pro-inflammatory cytokines. Some miRNAs, such as miR-146a, miR-146, and miR-155, play critical roles in regulating immune response by targeting key components of the TLR signaling pathway. This regulation results in adjustment of inflammatory and immune responses. TLRs: Toll-like receptors; MyD88: Myeloid differentiation primary response 88; IRAK4: IL-1 receptor associated kinase 4; IRAK1/2: IL-1 receptor associated kinase 1/2; TRAF6: TNF receptor-associated factor 6; TAK1: Transforming growth factor- β -activated kinase-1; TAB2: Transforming growth factor- β -activated kinase 1 (TAK1)-binding protein 2; TAB3: Transforming growth factor- β -activated kinase 1 (TAK1)-binding protein 3; NF- κ B: Nuclear factor kappa B; IKK α : inhibitory- κ B kinase α ; IKK β : inhibitory- κ B kinase β .

Key miRNAs in innate immune system

MiRNAs have been demonstrated to regulate innate immune system and inflammatory responses, adaptive immune responses by controlling B and T cells' development. They also facilitate communication between immune system and local cells. They play a remarkable role in sustaining inflammatory reactions (23). Disruption of miRNA biogenesis through the removal of Dicer1, leading to reduced miRNA levels in macrophages, has been linked to decreased inflammatory cytokine production in response to innate immune activation by various TLR ligands. This highlights the essential role of certain miRNAs in shaping inflammatory responses (24). For instance, the expression levels of some miRNAs such as miR-21, miR-9, miR-146, miR-147, and miR-155 are upregulated during the infection-induced inflammatory responses in macrophages (25).

Moreover, mir-155, -146, -21, and -9 act as suppressors of TLR signaling by targeting the mRNAs of these genes at the posttranscriptional level (26). Here are some microRNAs that have substantial roles in regulating innate immune system.

MiR-146

MiR-146a is a critical regulator of various processes in the innate and adaptive immune systems, such as inflammation, differentiation, and the function of immune cells (25). NF- κ B binds to the promoter of miR-146a to regulate its expression. Following the stimulation of TLRs, tumor necrosis factor receptors (TNFRs), IL1Rs, and receptor for advanced glycation end products (RAGE) are activated and both miR-146a and b are upregulated (24).

Genes like TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor associated kinase 1 (IRAK1), which control TLRs and cytokine receptors are suppressed by miR-146. Consequently, the immune response is modulated by miR-146 (24).

MiR-155

TLR family can regulate miR-155 expression. Expression levels of miR-155 increases upon stimulation of TLR4, TLR8, and TLR9 (27, 28), while activation of TLR7 signaling inhibits miR-155 expression. Additionally, TLR3 signaling is modulated by miR-155 (29).

The MiR-155 is upregulated in TLR4/MyD88/NF- κ B signaling pathway in the CD14⁺ monocytes that leads to the positive modulation of pro-inflammatory cytokines, oxidative stress, and proliferation rate in psoriasis patients (29). In addition, this microRNA plays a considerable role in regulating TLR signaling and the inflammatory response by targeting cytokine signal suppressor 1 (SOCS1), a negative regulator of TLR signaling (30). MiR-155 negatively regulates TLR signaling by targeting molecules such as TAB2, MyD88, IKK ϵ , RIPK1, C/EBP β , eNOS, and NF- κ B subunit p65, which are all involved in TLR signaling (24). In fibroblasts of synovial fluid in rheumatoid arthritis, the expression of miR-155 is induced by TNF- α stimulation, which in turn inhibits IL-6-mediated JAK2/STAT3 activation (31).

MiR-223

MiR-223 serves as a crucial regulator of innate immune responses, controlling myeloid differentiation and granulocyte functions (23). Upon activation of TLR9, binding of NF- κ B to the miR-223 promoter is enhanced, leading to the upregulation of miR223. Conversely, miR-223 targets I κ B kinase α expression, thereby reducing TLR9/NF- κ B-mediated inflammation (32). Activation of innate immune responses and initiation of adaptive immunity require differentiation of monocytes into macrophages (33). During this process, the expression levels of miR-223, miR-15, and miR-16 decrease, a response induced by inflammatory stimuli like Phorbol 12-myristate 13-acetate (PMA) and bacterial lipopolysaccharides (LPS) (23).

Let-7

Certain studies have shown a connection between members of let-7 family and innate immune responses to the pathogenic infections and stress. Let-7 family members regulate TLR4 in order to modulate innate immune responses and level of inflammation in response to *Pseudomonas aeruginosa* or *Helicobacter pylori* infections (34-36). The activation of NF- κ B and various genes involved in inflammation is controlled by TLR4. In addition, let-7 suppresses TLR4, thereby reducing innate immune response and inflammation during infection (37).

MiR-21

MiR-21 is one of crucial and significant regulators within the immune system. It negatively regulates TLR4 by targeting the pro-inflammatory tumor suppressor gene, PDCD4 (38). Furthermore, miR-21 plays a pivotal role in macrophage polarization (39). Circulating miR-21 can function as a ligand for TLR7 and TLR8 and then, subsequently leading to an increase in TNF- α and IL-6 production by macrophages (40).

MiR-9

MiR-9 is induced by TLR2, 4, 7, and 8, regulating the production of pro-inflammatory cytokines. It plays a key role in restoring homeostasis following immune activation through targeting NF- κ B signaling (24). In the context of macrophage activation, CCL2 supports classical immune activation, where miR-9 downregulates Dusp6, potentially enhancing ERK-mediated signal transduction and leading to increased expression of proinflammatory genes (41). Furthermore, miR-9 targets JAK1 and inhibits the activation of the NLRP3 inflammasome in THP-1-derived macrophages (42). Thus, MiR-9 has dual functionality in both enhancing and suppressing innate immune responses.

MiRNAs in autoimmunity and infectious diseases

Considering the regulatory role of miRNAs in the innate immune system, the disorders of this system could be related to dysregulated expression of miRNAs (43). Due to their stability and abundance, miRNAs could be potential biomarkers for early diagnosing of cancer and cardiovascular disorders (44, 45). Some pathways including NF- κ B dysregulation and interferon activation are involved in autoimmunity process (46).

Some animal and human studies have suggested that miRNAs may serve as a diagnostic biomarker or have therapeutic potential for infectious diseases and autoimmunity (47-50,51-53). MiRNAs have also been applied for evaluation of response to treatment in rheumatoid arthritis and Behcet disease (52,53) (tables 1 and 2).

Table 1. Animal studies indicating the role of miRNAs in infectious diseases and autoimmunity.

Animal model	MiRNA	Result	Year
Tuberculosis	miR-155	miR-155 up-regulated and key factor in immune response	2015 (47)
Zika virus Infection	miR-9	miR-9 up-regulated and induced microcephaly	2018 (48)
Keratitis induced by Fusarium solani	miR-223	MiR-223-3p regulates autophagy and is associated with the inflammatory response	2022 (49)
Multiple sclerosis	Let-7	Let-7 directly targets the cytokine receptors IL1R1 and IL23R, and negatively regulates Th17 cells differentiation	2019 (50)

MiRNA's therapeutic potential for different diseases

In the hippocampal tissue of rats with temporal lobe epilepsy (TLE), the expression levels of TNF- α and miR-155 are increased. Therefore, inhibition of the expression of miR-155 could prevent production of TNF- α (54).

In cystic fibrosis (CF), increased expression of miR-146a reduced the IL-6 production in macrophages, which could enhance the inflammatory responses of miRNAs in the macrophages. In particular, IL-6 production by CF macrophages in response to Lipopolysaccharide (LPS) stimulation appears to be the result of increased simultaneous of pro-inflammatory activities of miRNAs. This dysregulation leads to decreased or increased TLR signaling (55).

The association between the expressions of miR-451 and the IL-6R gene were investigated in RKO colon cancer cells and Hela cervical cancer cells. It was found that miR-451 reduced the expression of IL-6R mRNA and protein in these cells. miR-451 suppressed cancer cell growth and angiogenesis by reducing IL-6R gene expression (56).

Treatment of mice models of both acute hepatitis and NASH by miR-233 analog (miR-223 3p) resulted in reducing of liver inflammation (57).

Injection of MRX34, a liposomal mimic of microRNA-34a (miR-34a), in combination with oral dexamethasone premedication was beneficial in patients with advanced solid tumors (58). Anti-miR-122 miravirsin found to be effective for treating patients with hepatitis C virus (HCV) (59).

Conclusion and Future Perspective

Numerous studies have highlighted the role of miRNAs in regulating inflammatory and immune responses. The question of whether inflammation triggers the expression of specific miRNAs or if dysregulation of miRNA expression initiates the inflammatory response remains unclear (60).

MiRNAs serve as valuable biomarkers for diagnosis due to their accessibility and high specificity (44,45). Several studies have explored the effects of miRNAs on molecular pathogenesis of various diseases by manipulating their expression levels. The expression of miR-146a and miR-155 plays a significant role in the repolarization mechanisms of M1 (TNF- α , IL-6) and M2 (MGL-1) macrophages, influencing the secretion of inflammatory factors. Inhibitors of miR-146a and miR-155 in human alveolar macrophages have been shown to increase TNF- α and IL-6 levels while decreasing mGluR-1 (MGL-1) expression in pneumonia patients compared to healthy individuals (61). Moreover, upregulation of miR-146 (via transfection of miR-146 mimics) led to a decrease in IL-6 and TNF- α expressions by disrupting the TLR4/NF- κ B signaling pathway, resulting in improved ovarian function in mice (62).

Table 2. Clinical studies indicating the role of miRNAs in autoimmunity and evaluation of response to treatment.

Disease	Medication	miRNA	Result	Year
Autoimmune Premature Ovarian Insufficiency	-	miR-21	Low expressions of miR-21 and Peli1 were detected in autoimmune POI mice model and patients.	2020 (51)
Rheumatoid Arthritis	Green tea extract	miR-125b miR-146a	miR-146a and miR-125 b expression levels could significantly predict clinical responses to green tea therapy.	2015 (52)
Behcet's Disease	Curcumin in nanocarrier	miRNA-181, miRNA-25 miRNA-326	Nanocurcumin supplementation decreased expression of miRNA-155, miRNA-181, miRNA-326 significantly and showed favorable effects in improving inflammatory factors and disease activity.	2022 (53)

MiR-21 has been shown to mitigate inflammation, cardiac dysfunction, and maladaptive remodeling post-myocardial infarction by targeting kelch repeat and BTB (POZ) domain containing 7 (KBTBD7) and inhibiting p38 and activation of NF- κ B signaling (63).

Drawing from past and current research, miRNAs have been solidified as pivotal regulators of immune system and inflammatory processes. With an extensive comprehension of miRNAs functionality, there is a promising outlook for their utilization as biomarkers in both diagnosis and therapy in the near future.

Declaration

Acknowledgements

Authors would like to express their gratitude to their colleagues in regenerative medicine department at Royan Institute.

Funding

Not applicable.

Conflicts of interest/Competing interests

The authors declare no conflict of interest.

Authors' contributions

FT and HKA contributed to data collection and manuscript drafting. MH involved in reviewing, editing, and final approval. MV involved in conception, design, reviewing, and final approval of the manuscript. All authors approved the final version for submission.

Ethical Consideration

Not applicable.

References

- McComb S, Thiriot A, Akache B, Krishnan L, Stark F. Introduction to the immune system. Immunoproteomics: methods and protocols. 2019:1-24.
- Turvey SE, Broide DH. Innate immunity. Journal of Allergy and Clinical Immunology. 2010 Feb 1;125(2):S24-32.
- Khajeh Alizadeh Attar M, Anwar MA, Eskian M, Keshavarz-Fathi M, Choi S, Rezaei N. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis. Medicinal Research Reviews. 2018 Sep;38(5):1469-84.
- Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet PA, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European journal of medicinal chemistry. 2020 May 1;193:112238.
- Wang Y, Zhang S, Li H, Wang H, Zhang T, Hutchinson MR, et al. Small-molecule modulators of toll-like receptors. Accounts of chemical research. 2020 Apr 1;53(5):1046-55.
- Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: significance, ligands, signaling pathways, and functions in mammals. International reviews of immunology. 2018 Jan 2;37(1):20-36.
- Virtue A, Wang H, Yang XF. MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. Journal of hematology & oncology. 2012 Dec;5:1-7.

8. Gebert LF, MacRae IJ. Regulation of microRNA function in animals. *Nature reviews Molecular cell biology*. 2019 Jan;20(1):21-37.
9. Yang H, Li M, Hu X, Xin T, Zhang S, Zhao G, et al. MicroRNA-dependent roles of Drosha and Pasha in the *Drosophila* larval ovary morphogenesis. *Developmental biology*. 2016 Aug 15;416(2):312-23.
10. Song JL, Stoeckius M, Maaskola J, Friedländer M, Stepicheva N, Juliano C, et al. Select microRNAs are essential for early development in the sea urchin. *Developmental biology*. 2012 Feb 1;362(1):104-13.
11. Remsburg C, Konrad K, Sampilo NF, Song JL. Analysis of microRNA functions. *Methods in Cell Biology*. 2019 Jan 1;151:323-34.
12. Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. *Nature Reviews Genetics*. 2016 Dec;17(12):719-32.
13. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome research*. 2009 Jan 1;19(1):92-105.
14. Desvignes T, Batzel P, Berezikov E, Eilbeck K, Eppig JT, McAndrews MS, et al. miRNA nomenclature: a view incorporating genetic origins, biosynthetic pathways, and sequence variants. *Trends in Genetics*. 2015 Nov 1;31(11):613-26.
15. Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny JL, Fontana P. Methods to investigate miRNA function: focus on platelet reactivity. *Thrombosis and haemostasis*. 2021 Apr;121(04):409-21.
16. O'connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. *Nature Reviews Immunology*. 2010 Feb;10(2):111-22.
17. Chandan K, Gupta M, Sarwat M. Role of host and pathogen-derived microRNAs in immune regulation during infectious and inflammatory diseases. *Frontiers in immunology*. 2020 Jan 24;10:3081.
18. Raisch J, Darfeuille-Michaud A, Nguyen HT. Role of microRNAs in the immune system, inflammation and cancer. *World journal of gastroenterology: WJG*. 2013 May 28;19(20):2985.
19. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. *Nature Reviews Immunology*. 2016 May;16(5):279-94.
20. Curtis AM, Fagundes CT, Yang G, Palsson-McDermott EM, Wochal P, McGettrick AF, et al. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. *Proceedings of the National Academy of Sciences*. 2015 Jun 9;112(23):7231-6.
21. O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. *Blood, The Journal of the American Society of Hematology*. 2011 Sep 15;118(11):2960-9.
22. Cichocki F, Felices M, McCullar V, Presnell SR, Al-Attar A, Lutz CT, et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. *The Journal of Immunology*. 2011 Dec 15;187(12):6171-5.
23. Yuan X, Berg N, Lee JW, Le TT, Neudecker V, Jing N, et al. MicroRNA miR-223 as regulator of innate immunity. *Journal of leukocyte biology*. 2018 Sep;104(3):515-24.
24. Nejad C, Stunden HJ, Gantier MP. A guide to miRNAs in inflammation and innate immune responses. *The FEBS journal*. 2018 Oct;285(20):3695-716.
25. Nahand JS, Karimzadeh MR, Nezamnia M, Fatemipour M, Khatami A, Jamshidi S, et al. The role of miR-146a in viral infection. *IUBMB life*. 2020 Mar;72(3):343-60.
26. Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. *Autoimmunity reviews*. 2021 May 1;20(5):102800.
27. Liu F, Fan H, Ren D, Dong G, Hu E, Ji J, et al. TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE. *European journal of immunology*. 2015 Jul;45(7):1934-45.
28. Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. *Journal of translational medicine*. 2012 Dec;10:1-0.

38 MicroRNAs in Innate Immunity; the Smart ...

29. Li J, Liu Y, Cao Y, Wang J, Zhao X, Jiao J, et al. Inhibition of miR-155 attenuates CD14⁺ monocyte-mediated inflammatory response and oxidative stress in psoriasis through TLR4/MyD88/NF- κ B signaling pathway. *Clinical, Cosmetic and Investigational Dermatology*. 2022 Feb 9;193-201.
30. Husakova M. MicroRNAs in the key events of systemic lupus erythematosus pathogenesis. *Biomedical Papers of the Medical Faculty of Palacky University in Olomouc*. 2016 Sep 1;160(3).
31. Banerjee S, Thompson WE, Chowdhury I. Emerging roles of microRNAs in the regulation of Toll-like receptor (TLR)-signaling. *Frontiers in bioscience (Landmark edition)*. 2021 Jan 1;26(4):771.
32. He Y, Feng D, Li M, Gao Y, Ramirez T, Cao H, et al. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. *Hepatology*. 2017 Jul;66(1):220-34.
33. León B, Ardavín C. Monocyte-derived dendritic cells in innate and adaptive immunity. *Immunology and cell biology*. 2008 Jun;86(4):320-4.
34. Zhi L, Yu Y, Li X, Wang D, Wang D. Molecular control of innate immune response to *Pseudomonas aeruginosa* infection by intestinal let-7 in *Caenorhabditis elegans*. *PLoS pathogens*. 2017 Jan 17;13(1):e1006152.
35. Ren Z, Ambros VR. *Caenorhabditis elegans* microRNAs of the let-7 family act in innate immune response circuits and confer robust developmental timing against pathogen stress. *Proceedings of the National Academy of Sciences*. 2015 May 5;112(18):E2366-75.
36. Teng GG, Wang WH, Dai Y, Wang SJ, Chu YX, Li J. Let-7b is involved in the inflammation and immune responses associated with *Helicobacter pylori* infection by targeting Toll-like receptor 4. *PloS one*. 2013 Feb 20;8(2):e56709.
37. Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, et al. MicroRNA let-7 and viral infections: focus on mechanisms of action. *Cellular & molecular biology letters*. 2022 Dec;27(1):14.
38. Momen-Heravi F, Bala S. miRNA regulation of innate immunity. *Journal of leukocyte biology*. 2018 Jun;103(6):1205-17.
39. Essandoh K, Li Y, Huo J, Fan GC. MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response. *Shock*. 2016 Aug 1;46(2):122-31.
40. Usuelli V, Loretelli C, Seelam AJ, Pastore I, D'Addio F, Nasr MB, et al. Novel soluble mediators of innate immune system activation in solid allograft rejection. *Transplantation*. 2022 Mar 1;106(3):500-9.
41. Carson IV WF, Salter-Green SE, Scola MM, Joshi A, Gallagher KA, Kunkel SL. Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6. *Cellular immunology*. 2017 Apr 1;314:63-72.
42. Wang C, You Q, Cao X, Guo H, Gao X, Peng X. Micro RNA-19a suppresses interleukin-10 in peripheral B cells of patients with diabetic retinopathy. *American journal of translational research*. 2017 Mar 15;9(3):1410.
43. Sekar D, Lakshmanan G. Methylation of N6-adenosine (m6A) modification in miRNAs and its implications in immunity. *Epigenomics*. 2020 Jul 1;12(13):1083-5.
44. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. *BioMed research international*. 2015;2015(1):125094.
45. Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, et al. miRNAs in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. *Acta Pharmacologica Sinica*. 2018 Jul;39(7):1073-84.
46. Savic S, Caseley EA, McDermott MF. Moving towards a systems-based classification of innate immune-mediated diseases. *Nature Reviews Rheumatology*. 2020 Apr;16(4):222-37.
47. Iwai H, Funatogawa K, Matsumura K, Kato-Miyazawa M, Kirikae F, Kiga K, Sasakawa C, et al. MicroRNA-155 knockout mice are susceptible to *Mycobacterium tuberculosis* infection. *Tuberculosis*. 2015 May 1;95(3):246-50.
48. Zhang H, Chang Y, Zhang L, Kim SN, Otaegi G, Zhang Z, et al. Upregulation of microRNA miR-9 is associated with microcephaly and Zika virus infection in mice. *Molecular Neurobiology*. 2019 Jun;56:4072-85.

49. Tang H, Lin Y, Huang L, Hu J. MiR-223-3p Regulates Autophagy and Inflammation by Targeting ATG16L1 in *Fusarium solani*-Induced Keratitis. *Investigative Ophthalmology & Visual Science*. 2022 Jan 3;63(1):41.
50. Angelou CC, Wells AC, Vijayaraghavan J, Dougan CE, Lawlor R, Iverson E, et al. Differentiation of pathogenic Th17 cells is negatively regulated by Let-7 microRNAs in a mouse model of multiple sclerosis. *Frontiers in immunology*. 2020 Jan 17;10:3125.
51. Li X, Xie J, Wang Q, Cai H, Xie C, Fu X. miR-21 and Pellino-1 Expression Profiling in Autoimmune Premature Ovarian Insufficiency. *Journal of immunology research*. 2020;2020(1):3582648.
52. Al-Rawaf HA, Alghadir AH, Gabr SA. Circulating microRNAs expression as predictors of clinical response in rheumatoid arthritis patients treated with green tea. *Journal of Herbal Medicine*. 2021 Jun 1;27:100363.
53. Farzaneh R, Khabbazi A, Soltani-Zangbar MS, Abbasian S, Malek Mahdavi A, Motavalli R, et al. Effects of nanocurcumin supplementation on T-helper 17 cells inflammatory response in patients with Behcet's disease: a randomized controlled trial. *Immunopharmacology and Immunotoxicology*. 2022 Mar 4;44(2):206-15.
54. Li TR, Jia YJ, Wang Q, Shao XQ, Zhang P, Lv RJ. Correlation between tumor necrosis factor alpha mRNA and microRNA-155 expression in rat models and patients with temporal lobe epilepsy. *Brain research*. 2018 Dec 1;1700:56-65.
55. Stachowiak Z, Wojsyk-Banaszak I, Jończyk-Potoczna K, Narożna B, Langwiński W, Szczepankiewicz A. Extracellular vesicles-derived miRNAs as mediators of pulmonary exacerbation in pediatric cystic fibrosis. *Journal of Breath Research*. 2023 Feb 10;17(2):026005.
56. Liu D, Liu C, Wang X, Ingvarsson S, Chen H. MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. *Cancer epidemiology*. 2014 Feb 1;38(1):85-92.
57. Calvente CJ, Del Pilar H, Tameda M, Johnson CD, Feldstein AE. MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury. *Molecular therapy*. 2020 Feb 5;28(2):653-63.
58. Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. *British journal of cancer*. 2020 May 26;122(11):1630-7.
59. Sarnow P, Sagan SM. Unraveling the mysterious interactions between hepatitis C virus RNA and liver-specific microRNA-122. *Annual review of virology*. 2016 Sep 29;3(1):309-32.
60. Chegini N. Uterine microRNA signature and consequence of their dysregulation in uterine disorders. *Animal reproduction/Colegio Brasileiro de Reproducao Animal*. 2010 Jul;7(3):117.
61. Yang Y, Wu BQ, Wang YH, Shi YF, Luo JM, Ba JH, et al. Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in vitro. *Immunopharmacology and immunotoxicology*. 2016 Nov 1;38(6):502-9.
62. He F, Liu Y, Li T, Ma Q, Yongmei Z, He P, et al. MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF-κB signaling pathway. *Bioengineered*. 2022 May 2;13(5):11611-23.
63. Yang L, Wang B, Zhou Q, Wang Y, Liu X, Liu Z, et al. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7. *Cell death & disease*. 2018 Jul 10;9(7):769.

How to cite this article: Fereshteh Takhiri, Hani Keshavarz Alikhani, Moustapha Hassan, Massoud Vosough. MicroRNAs in Innate Immunity; the Smart Regulatory Network. *Mod Med Lab J*. 2024;7(1): 31-39.